PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31882422-5 2019 The effects of TSLP-DCs and treatments with FK506, an NFATc1 inhibitor, on naive T cell differentiation were monitored by measuring the interleukin (IL)-4, IL-13, and interferon-gamma (IFN-gamma) expression levels. Tacrolimus 44-49 nuclear factor of activated T cells 1 Homo sapiens 54-60 25491283-8 2015 Immunohistologic analyses on granuloma showed that tacrolimus caused a significant reduction in the number of TRAP-positive osteoclasts and NFATc1 nuclear staining in multinucleated giant cells. Tacrolimus 51-61 nuclear factor of activated T cells 1 Homo sapiens 140-146 31087207-11 2019 These results suggest that tacrolimus is neuroprotective against axon loss in TNF-induced optic neuropathy and that the effect arises from suppression of the CaN/NFATc1 pathway. Tacrolimus 27-37 nuclear factor of activated T cells 1 Homo sapiens 162-168 30036394-7 2018 In vitro experiments revealed that 50 ng/ml tacrolimus affected NFATc1 amplification by 58% (mean; p = 0.02). Tacrolimus 44-54 nuclear factor of activated T cells 1 Homo sapiens 64-70 26361868-10 2015 Inhibition of the calcineurin/NFATc1 pathway by cyclosporin A and FK506, attenuated Tbeta4-induced osteoblastic differentiation and activation of Wnt-related genes, as well as nuclear beta-catenin in hPDLCs. Tacrolimus 66-71 nuclear factor of activated T cells 1 Homo sapiens 30-36 25631176-0 2015 The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. Tacrolimus 70-80 nuclear factor of activated T cells 1 Homo sapiens 12-18 25631176-7 2015 In prostate cancer cell lines, CsA and FK506 inhibited NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of c-myc, a downstream target of NFAT. Tacrolimus 39-44 nuclear factor of activated T cells 1 Homo sapiens 55-61 25631176-12 2015 Thus, NFATc1 inactivation, especially using CsA and FK506, has the potential of being a therapeutic approach for not only hormone-naive but also castration-resistant prostate cancers. Tacrolimus 52-57 nuclear factor of activated T cells 1 Homo sapiens 6-12 30036394-0 2018 Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. Tacrolimus 78-88 nuclear factor of activated T cells 1 Homo sapiens 12-18 30036394-2 2018 Here, we tested whether measuring NFATc1 amplification, a member of the calcineurin pathway, is suitable for TDM of tacrolimus. Tacrolimus 116-126 nuclear factor of activated T cells 1 Homo sapiens 34-40 30036394-3 2018 MATERIALS AND METHODS: NFATc1 amplification was monitored in T cells of kidney transplant recipients who received either tacrolimus- (n = 11) or belatacept-based (n = 10) therapy. Tacrolimus 121-131 nuclear factor of activated T cells 1 Homo sapiens 23-29 30036394-5 2018 RESULTS: At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus 45-55 nuclear factor of activated T cells 1 Homo sapiens 74-80 30036394-6 2018 Tacrolimus pre-dose concentrations of these patients correlated inversely with NFATc1 amplification in CD28+ T cells (rs = -0.46; p < 0.01). Tacrolimus 0-10 nuclear factor of activated T cells 1 Homo sapiens 79-85 30036394-8 2018 CONCLUSION: In conclusion, measuring NFATc1 amplification is a direct tool for monitoring biological effects of tacrolimus on T cells in whole blood samples of kidney transplant recipients. Tacrolimus 112-122 nuclear factor of activated T cells 1 Homo sapiens 37-43 25638160-4 2015 In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1. Tacrolimus 55-65 nuclear factor of activated T cells 1 Homo sapiens 293-299 25638160-0 2015 Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Tacrolimus 19-29 nuclear factor of activated T cells 1 Homo sapiens 87-93 25638160-4 2015 In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1. Tacrolimus 55-65 nuclear factor of activated T cells 1 Homo sapiens 141-147 25638160-4 2015 In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1. Tacrolimus 67-72 nuclear factor of activated T cells 1 Homo sapiens 141-147 25638160-4 2015 In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1. Tacrolimus 67-72 nuclear factor of activated T cells 1 Homo sapiens 293-299 25638160-9 2015 Thus, NFATc1 inactivation, especially using CsA and FK506, has the potential of being a therapeutic approach for bladder cancer. Tacrolimus 52-57 nuclear factor of activated T cells 1 Homo sapiens 6-12 16586042-6 2007 Addition of tacrolimus or cyclosporine A resulted in a decrease in the number of TRAP-positive multinucleated cells (TRAP+ MNCs) and a decrease in the extent of lacunar resorption pit formation as compared to the control cultures; thus, human monocyte-osteoclast differentiation was more effectively inhibited at the late stage and addition of tacrolimus or cyclosporine A resulted in a decrease in the mRNA expression of NFATc1, c-Jun, and MITF at the late stage. Tacrolimus 12-22 nuclear factor of activated T cells 1 Homo sapiens 422-428 25226517-11 2014 Actin lamellipodia formation as well as FAK and beta6-integrin expression were also significantly decreased after treatment with FK506 or siRNA, reinforcing that NFAT2-dependent T-plastin expression plays a role in keratinocyte migration. Tacrolimus 129-134 nuclear factor of activated T cells 1 Homo sapiens 162-167 25226517-9 2014 The expression of NFAT2 and T-plastin in keratinocytes was decreased under FK506 treatment, suggesting that T-plastin plays a role in keratinocyte migration downstream to the calcineurin/NFAT pathway. Tacrolimus 75-80 nuclear factor of activated T cells 1 Homo sapiens 18-23 23732701-1 2013 Cyclosporine A and FK506 produce immunosuppression by blocking calcineurin phosphatase activity and consequently activation of cytosolic Nuclear Factor of Activated T-cell (NFATc) transcription factor. Tacrolimus 19-24 nuclear factor of activated T cells 1 Homo sapiens 173-178 23000414-5 2012 Treatment with calcineurin-NFAT inhibitors, Tacrolimus (FK506) and the 11R-VIVIT (VIVIT) peptide, reduces NFATc1 expression consistent with a reduction in osteoclast differentiation and activity. Tacrolimus 44-54 nuclear factor of activated T cells 1 Homo sapiens 106-112 23000414-5 2012 Treatment with calcineurin-NFAT inhibitors, Tacrolimus (FK506) and the 11R-VIVIT (VIVIT) peptide, reduces NFATc1 expression consistent with a reduction in osteoclast differentiation and activity. Tacrolimus 56-61 nuclear factor of activated T cells 1 Homo sapiens 106-112 23000414-9 2012 Quantitative real-time polymerase chain reaction (qRT-PCR) analysis demonstrated that FK506 treatment significantly (p<0.05) reduced the expression of NFATc1, CathK, OSCAR, FcRgamma, TREM2 and DAP12 during the terminal stage of osteoclast formation. Tacrolimus 86-91 nuclear factor of activated T cells 1 Homo sapiens 154-160 17196174-6 2007 The calcineurin inhibitors, tacrolimus (FK506) and cyclosporin A, had no effect on cell migration but completely blocked both cytokine production and the nuclear translocation of NFATc1 suggesting that Ca2+/calcineurin/NFAT is involved in CRTH2-dependent cytokine production but not chemotaxis. Tacrolimus 28-38 nuclear factor of activated T cells 1 Homo sapiens 179-185 17196174-6 2007 The calcineurin inhibitors, tacrolimus (FK506) and cyclosporin A, had no effect on cell migration but completely blocked both cytokine production and the nuclear translocation of NFATc1 suggesting that Ca2+/calcineurin/NFAT is involved in CRTH2-dependent cytokine production but not chemotaxis. Tacrolimus 40-45 nuclear factor of activated T cells 1 Homo sapiens 179-185 15716327-1 2005 Cyclosporin A (CsA) and FK506 suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFATc), which are central regulators of T cell function. Tacrolimus 24-29 nuclear factor of activated T cells 1 Homo sapiens 172-177 16046394-5 2005 Here we demonstrate that the expression of OSCAR, but not that of TREM-2, is up-regulated during osteoclastogenesis and markedly suppressed by the calcineurin inhibitor FK506, suggesting that OSCAR is transcriptionally regulated by NFATc1. Tacrolimus 169-174 nuclear factor of activated T cells 1 Homo sapiens 232-238 12195013-6 2002 This enhancement was nearly abolished by blocking the nuclear translocation of NFATc by using the calcineurin inhibitor FK506. Tacrolimus 120-125 nuclear factor of activated T cells 1 Homo sapiens 79-84 11897999-10 2002 NFAT2 protein accumulated in the nuclei of basophils activated for 1 hour with anti-IgE, and this was inhibited with the addition of FK506. Tacrolimus 133-138 nuclear factor of activated T cells 1 Homo sapiens 0-5 9515963-5 1998 Treatment of wild-type embryos with FK506, a specific calcineurin inhibitor, prevents nuclear localization of NF-ATc. Tacrolimus 36-41 nuclear factor of activated T cells 1 Homo sapiens 110-116 9349628-1 1997 The clinically important immunosuppressant drugs cyclosporin A and FK506 (tacrolimus) inhibit in T-cells calcineurin phosphatase activity and nuclear translocation of the cytosolic component of the transcription factor nuclear factor of activated T-cells (NF-ATc) that is involved in the induction of early genes during T-cell activation. Tacrolimus 67-72 nuclear factor of activated T cells 1 Homo sapiens 256-262 9349628-1 1997 The clinically important immunosuppressant drugs cyclosporin A and FK506 (tacrolimus) inhibit in T-cells calcineurin phosphatase activity and nuclear translocation of the cytosolic component of the transcription factor nuclear factor of activated T-cells (NF-ATc) that is involved in the induction of early genes during T-cell activation. Tacrolimus 74-84 nuclear factor of activated T cells 1 Homo sapiens 256-262 7887301-4 1994 The activation of calcineurin and the nuclear import of NF-ATc can both be blocked by cyclosporin A or FK506 in complex with their respective immunophilins. Tacrolimus 103-108 nuclear factor of activated T cells 1 Homo sapiens 56-62